$18.4 Billion is the total value of Baker Brothers Advisors's 105 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 19.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Buy | Seagen Inc. | $9,498,630,809 | +57.6% | 46,913,769 | +0.0% | 51.68% | +42.7% |
| INCY | Buy | Incyte Corporation | $2,614,396,158 | -10.0% | 36,175,400 | +0.1% | 14.22% | -18.4% |
| BGNE | BeiGene, Ltd.sponsored adr | $2,514,997,370 | -2.0% | 11,668,897 | 0.0% | 13.68% | -11.2% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $789,282,307 | +18.3% | 41,938,486 | +0.0% | 4.29% | +7.1% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $374,319,075 | -16.5% | 1,545,113 | 0.0% | 2.04% | -24.4% | |
| BMRN | Sell | BioMarin Pharmaceutical Inc. | $370,508,516 | -53.0% | 3,810,248 | -50.0% | 2.02% | -57.4% |
| IMCR | Immunocore Holdings plcads | $124,624,941 | -13.4% | 2,520,731 | 0.0% | 0.68% | -21.5% | |
| RYTM | Buy | Rhythm Pharmaceuticals, Inc. | $115,929,083 | -37.4% | 6,498,267 | +2.3% | 0.63% | -43.2% |
| KOD | Kodiak Sciences Inc. | $107,325,038 | -13.4% | 17,310,490 | 0.0% | 0.58% | -21.5% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $106,008,222 | -27.4% | 12,710,818 | 0.0% | 0.58% | -34.1% | |
| ARGX | argenx SEsponsored adr | $104,381,640 | -1.6% | 280,159 | 0.0% | 0.57% | -10.8% | |
| AKRO | Akero Therapeutics, Inc. | $90,614,142 | -30.2% | 2,368,378 | 0.0% | 0.49% | -36.7% | |
| KYMR | Kymera Therapeutics, Inc. | $85,329,215 | +18.7% | 2,879,825 | 0.0% | 0.46% | +7.4% | |
| REPL | Replimune Group, Inc. | $80,852,425 | -35.1% | 4,578,280 | 0.0% | 0.44% | -41.2% | |
| ABCL | AbCellera Biologics Inc. | $78,794,357 | -25.6% | 10,450,180 | 0.0% | 0.43% | -32.5% | |
| SWTX | Buy | SpringWorks Therapeutics, Inc. | $70,875,141 | +78.3% | 2,753,502 | +80.1% | 0.39% | +61.5% |
| Entrada Therapeutics, Inc. | $70,554,376 | +7.2% | 4,865,819 | 0.0% | 0.38% | -2.8% | ||
| BMEA | Buy | Biomea Fusion, Inc. | $65,398,508 | +268.6% | 2,108,949 | +0.2% | 0.36% | +232.7% |
| RVMD | Buy | Revolution Medicines, Inc. | $58,297,738 | +1001.3% | 2,691,493 | +1111.2% | 0.32% | +890.6% |
| PRLD | Prelude Therapeutics Inc. | $57,705,797 | -5.6% | 10,123,824 | 0.0% | 0.31% | -14.4% | |
| MRTX | Mirati Therapeutics, Inc. | $52,415,769 | -17.9% | 1,409,784 | 0.0% | 0.28% | -25.8% | |
| FGEN | Buy | FibroGen, Inc. | $49,213,585 | +123.4% | 2,637,384 | +91.8% | 0.27% | +103.0% |
| CERS | Cerus Corporation | $47,720,647 | -18.6% | 16,067,558 | 0.0% | 0.26% | -26.1% | |
| IGMS | Buy | IGM Biosciences, Inc. | $43,372,453 | -19.2% | 3,156,656 | +0.0% | 0.24% | -26.7% |
| AVTE | Sell | Aerovate Therapeutics, Inc. | $39,603,371 | -31.6% | 1,963,479 | -0.7% | 0.22% | -38.2% |
| IMTX | Immatics N.V. | $35,790,859 | -20.8% | 5,187,081 | 0.0% | 0.20% | -28.0% | |
| Buy | Roivant Sciences Ltd. | $35,257,433 | +515.7% | 4,777,430 | +566.6% | 0.19% | +464.7% | |
| NRIX | Nurix Therapeutics, Inc. | $34,473,270 | -19.1% | 3,882,125 | 0.0% | 0.19% | -26.6% | |
| KDNY | Sell | Chinook Therapeutics, Inc. | $33,687,926 | -49.3% | 1,455,202 | -42.6% | 0.18% | -54.1% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $30,123,449 | -28.2% | 2,799,577 | 0.0% | 0.16% | -34.9% | |
| Buy | DICE Therapeutics, Inc. | $29,675,269 | +10.3% | 1,035,786 | +20.1% | 0.16% | -0.6% | |
| XENE | Xenon Pharmaceuticals Inc. | $26,901,160 | -9.2% | 751,639 | 0.0% | 0.15% | -18.0% | |
| Buy | 2seventy bio, Inc. | $25,474,765 | +31.8% | 2,497,526 | +21.1% | 0.14% | +19.8% | |
| DNLI | Denali Therapeutics Inc. | $25,084,524 | -17.2% | 1,088,738 | 0.0% | 0.14% | -25.3% | |
| DBVT | DBV Technologies S.A.sponsored adr | $24,698,106 | +10.5% | 14,614,264 | 0.0% | 0.13% | 0.0% | |
| KRYS | Krystal Biotech, Inc. | $24,235,443 | +1.1% | 302,716 | 0.0% | 0.13% | -8.3% | |
| VERV | Verve Therapeutics, Inc. | $20,426,363 | -25.5% | 1,416,530 | 0.0% | 0.11% | -32.7% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $18,886,057 | -13.4% | 470,974 | 0.0% | 0.10% | -21.4% | |
| BCYC | Bicycle Therapeutics plcsponsored ads | $17,947,924 | -28.1% | 843,814 | 0.0% | 0.10% | -34.7% | |
| STOK | Buy | Stoke Therapeutics, Inc. | $17,621,415 | +72.2% | 2,115,416 | +90.8% | 0.10% | +57.4% |
| ANAB | AnaptysBio, Inc. | $16,884,106 | -29.8% | 775,924 | 0.0% | 0.09% | -36.1% | |
| RNA | Buy | Avidity Biosciences, Inc. | $15,412,183 | +59.7% | 1,004,051 | +130.9% | 0.08% | +44.8% |
| BPMC | New | Blueprint Medicines Corporation | $15,011,588 | – | 333,665 | +100.0% | 0.08% | – |
| SBTX | ARS Pharmaceuticals, Inc. | $13,061,996 | -23.7% | 2,006,451 | 0.0% | 0.07% | -31.1% | |
| PACB | Pacific Biosciences of California, Inc. | $13,059,716 | +41.6% | 1,127,782 | 0.0% | 0.07% | +29.1% | |
| Prime Medicine, Inc. | $12,650,132 | -33.8% | 1,028,466 | 0.0% | 0.07% | -40.0% | ||
| HRTX | Heron Therapeutics, Inc. | $12,278,834 | -39.6% | 8,131,678 | 0.0% | 0.07% | -45.1% | |
| NVTA | Buy | Invitae Corporation | $11,989,490 | -23.3% | 8,881,104 | +5.7% | 0.06% | -30.9% |
| IDYA | Sell | IDEAYA Biosciences, Inc. | $11,433,918 | -62.3% | 832,769 | -50.1% | 0.06% | -65.9% |
| SMMT | Buy | Summit Therapeutics Inc. | $11,033,234 | +29.8% | 6,304,705 | +215.2% | 0.06% | +17.6% |
| CABA | Cabaletta Bio, Inc. | $11,114,880 | -10.6% | 1,344,000 | 0.0% | 0.06% | -20.0% | |
| OPT | Opthea Limitedsponsored ads | $10,630,994 | -26.3% | 2,691,391 | 0.0% | 0.06% | -33.3% | |
| VSTM | Sell | Verastem, Inc. | $10,596,505 | -2.5% | 25,521,447 | -5.4% | 0.06% | -10.8% |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $10,715,656 | -25.3% | 9,830,877 | 0.0% | 0.06% | -32.6% | |
| FATE | Buy | Fate Therapeutics, Inc. | $9,528,787 | +337.8% | 1,671,717 | +675.0% | 0.05% | +300.0% |
| PNT | POINT Biopharma Global Inc. | $8,499,379 | -0.3% | 1,169,103 | 0.0% | 0.05% | -9.8% | |
| BLUE | bluebird bio, Inc. | $7,949,094 | -54.0% | 2,499,715 | 0.0% | 0.04% | -58.7% | |
| ALLO | New | Allogene Therapeutics, Inc. | $7,789,891 | – | 1,576,901 | +100.0% | 0.04% | – |
| MRSN | New | Mersana Therapeutics, Inc. | $7,751,933 | – | 1,886,115 | +100.0% | 0.04% | – |
| Aadi Bioscience, Inc. | $7,167,079 | -43.6% | 989,928 | 0.0% | 0.04% | -48.7% | ||
| Buy | Sera Prognostics, Inc. | $6,851,870 | +2597.9% | 1,789,000 | +787.6% | 0.04% | +1750.0% | |
| SANA | New | Sana Biotechnology, Inc. | $6,540,000 | – | 2,000,000 | +100.0% | 0.04% | – |
| GERN | New | Geron Corporation | $6,642,856 | – | 3,061,224 | +100.0% | 0.04% | – |
| MGNX | MacroGenics, Inc. | $6,399,791 | +6.9% | 892,579 | 0.0% | 0.04% | -2.8% | |
| ARAV | Aravive, Inc. | $6,522,448 | +51.5% | 3,261,224 | 0.0% | 0.04% | +34.6% | |
| TScan Therapeutics, Inc. | $5,848,063 | +35.5% | 2,784,792 | 0.0% | 0.03% | +23.1% | ||
| ALEC | Buy | Alector, Inc. | $5,972,428 | -5.1% | 964,851 | +41.5% | 0.03% | -15.8% |
| ATHA | Buy | Athira Pharma, Inc. | $5,875,888 | -1.4% | 2,350,355 | +25.0% | 0.03% | -11.1% |
| INSM | Buy | Insmed Incorporated | $5,848,150 | +1367.2% | 343,000 | +1619.3% | 0.03% | +1500.0% |
| NTRA | Natera, Inc. | $5,552,000 | +38.2% | 100,000 | 0.0% | 0.03% | +25.0% | |
| CMPX | Compass Therapeutics, Inc. | $5,093,450 | -35.0% | 1,557,630 | 0.0% | 0.03% | -40.4% | |
| AFMD | Affimed N.V. | $4,918,596 | -39.9% | 6,596,830 | 0.0% | 0.03% | -44.9% | |
| RLAY | New | Relay Therapeutics, Inc. | $4,677,480 | – | 284,000 | +100.0% | 0.02% | – |
| BCEL | Atreca, Inc. | $4,027,346 | +42.4% | 3,532,760 | 0.0% | 0.02% | +29.4% | |
| IPSC | Century Therapeutics, Inc. | $3,988,210 | -32.4% | 1,149,340 | 0.0% | 0.02% | -37.1% | |
| DSGN | Sell | Design Therapeutics, Inc. | $3,617,121 | -49.1% | 626,884 | -9.4% | 0.02% | -53.5% |
| TLIS | Talis Biomedical Corporation | $3,736,169 | +9.9% | 7,624,835 | 0.0% | 0.02% | 0.0% | |
| VOR | Sell | Vor Biopharma Inc. | $3,410,102 | -65.0% | 633,848 | -56.8% | 0.02% | -67.8% |
| XNCR | Xencor, Inc. | $3,434,012 | +7.1% | 123,127 | 0.0% | 0.02% | 0.0% | |
| TIL | Instil Bio, Inc. | $3,484,920 | +4.9% | 5,273,789 | 0.0% | 0.02% | -5.0% | |
| EWTX | Edgewise Therapeutics, Inc. | $3,335,000 | -25.4% | 500,000 | 0.0% | 0.02% | -33.3% | |
| Tango Therapeutics, Inc. | $2,962,500 | -45.5% | 750,000 | 0.0% | 0.02% | -51.5% | ||
| GLUE | New | Monte Rosa Therapeutics, Inc. | $2,921,990 | – | 375,095 | +100.0% | 0.02% | – |
| NLTX | Neoleukin Therapeutics, Inc. | $2,675,218 | +37.5% | 3,821,740 | 0.0% | 0.02% | +25.0% | |
| LPTX | Buy | Leap Therapeutics, Inc. | $2,524,694 | +902.4% | 7,425,570 | +1226.7% | 0.01% | +600.0% |
| HOOK | HOOKIPA Pharma Inc. | $2,557,994 | -9.1% | 3,475,535 | 0.0% | 0.01% | -17.6% | |
| VERA | Vera Therapeutics, Inc.cl a | $2,586,664 | -59.9% | 333,333 | 0.0% | 0.01% | -64.1% | |
| ACHL | Achilles Therapeutics plcsponsored ads | $2,481,233 | +6.4% | 2,591,366 | 0.0% | 0.01% | -7.1% | |
| ATRA | Atara Biotherapeutics, Inc. | $2,158,139 | -11.6% | 744,186 | 0.0% | 0.01% | -20.0% | |
| ITOS | iTeos Therapeutics, Inc. | $2,046,209 | -30.3% | 150,346 | 0.0% | 0.01% | -38.9% | |
| PCVX | Vaxcyte, Inc. | $1,832,210 | -21.8% | 48,885 | 0.0% | 0.01% | -28.6% | |
| ALGS | Aligos Therapeutics, Inc. | $1,814,774 | -8.3% | 2,076,400 | 0.0% | 0.01% | -16.7% | |
| VERU | Veru Inc. | $1,867,112 | -78.0% | 1,609,579 | 0.0% | 0.01% | -80.4% | |
| PMVP | PMV Pharmaceuticals, Inc. | $1,536,054 | -45.2% | 322,024 | 0.0% | 0.01% | -52.9% | |
| NKTX | Nkarta, Inc. | $1,420,000 | -40.7% | 400,000 | 0.0% | 0.01% | -42.9% | |
| PRAX | Buy | Praxis Precision Medicines, Inc. | $1,520,851 | -65.1% | 1,879,915 | +2.7% | 0.01% | -69.2% |
| TCRR | TCR2 Therapeutics Inc. | $1,129,596 | +50.2% | 753,064 | 0.0% | 0.01% | +20.0% | |
| Kala Pharmaceuticals, Inc. | $1,156,036 | -60.6% | 76,813 | 0.0% | 0.01% | -66.7% | ||
| AGLE | Aeglea BioTherapeutics, Inc. | $988,931 | -35.5% | 3,410,106 | 0.0% | 0.01% | -44.4% | |
| TARA | Protara Therapeutics, Inc. | $624,970 | +16.8% | 199,671 | 0.0% | 0.00% | 0.0% | |
| GTH | Genetron Holdings Limitedads | $478,071 | -6.3% | 455,306 | 0.0% | 0.00% | 0.0% | |
| FHTX | Foghorn Therapeutics Inc. | $279,167 | -2.8% | 45,027 | 0.0% | 0.00% | 0.0% | |
| VINC | Vincerx Pharma, Inc. | $251,034 | +2.0% | 241,379 | 0.0% | 0.00% | 0.0% | |
| Bellicum Pharmaceuticals, Inc. | $82,211 | -54.2% | 249,123 | 0.0% | 0.00% | -100.0% | ||
| Surrozen, Inc.w exp 8/11/2026 | $83,333 | +81.5% | 833,333 | 0.0% | 0.00% | – | ||
| LIFE | Exit | aTyr Pharma, Inc. | $0 | – | -8,565 | -100.0% | 0.00% | – |
| KZR | Exit | Kezar Life Sciences, Inc. | $0 | – | -61,946 | -100.0% | -0.00% | – |
| KRON | Exit | Kronos Bio, Inc. | $0 | – | -1,198,151 | -100.0% | -0.01% | – |
| CYT | Exit | Cyteir Therapeutics, Inc. | $0 | – | -2,492,118 | -100.0% | -0.02% | – |
| Exit | Biohaven Ltd. | $0 | – | -476,190 | -100.0% | -0.04% | – | |
| Exit | Invitae Corporationnote 2.0% 9/1/2024 | $0 | – | -10,300,000 | -100.0% | -0.05% | – | |
| RETA | Exit | Reata Pharmaceuticals, Inc.cl a | $0 | – | -223,976 | -100.0% | -0.05% | – |
| Exit | CinCor Pharma, Inc. | $0 | – | -807,212 | -100.0% | -0.06% | – | |
| ALT | Exit | Altimmune, Inc. | $0 | – | -653,562 | -100.0% | -0.06% | – |
| Exit | Zymeworks Inc. | $0 | – | -1,708,472 | -100.0% | -0.08% | – | |
| CBAY | Exit | CymaBay Therapeutics, Inc. | $0 | – | -2,170,464 | -100.0% | -0.08% | – |
| Exit | Insmed Incorporatednote 0.75% 6/1/2028 | $0 | – | -23,500,000 | -100.0% | -0.12% | – | |
| TVTX | Exit | Travere Therapeutics, Inc. | $0 | – | -1,225,255 | -100.0% | -0.16% | – |
| HZNP | Exit | Horizon Therapeutics Public Ltd Co | $0 | – | -969,727 | -100.0% | -0.66% | – |
| ASND | Exit | Ascendis Pharma A/Ssponsored adr | $0 | – | -4,954,855 | -100.0% | -3.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 40 | Q1 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 40 | Q1 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 40 | Q1 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 40 | Q1 2023 | 1.7% |
| Cerus Corporation | 40 | Q1 2023 | 0.9% |
| Insmed Incorporated | 40 | Q1 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 39 | Q1 2023 | 1.8% |
| Bluebird Bio Inc. | 39 | Q1 2023 | 0.3% |
| Heron Therapeutics, Inc. | 37 | Q1 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| 2seventy bio, Inc. | February 14, 2023 | 2,062,744 | 5.4% |
| Achilles Therapeutics plc | February 14, 2023 | 4,207,733 | 9.9% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Aerovate Therapeutics, Inc. | February 14, 2023 | 1,976,868 | 8.0% |
| Akero Therapeutics, Inc. | February 14, 2023 | 2,368,378 | 5.1% |
| Aravive, Inc. | February 14, 2023 | 4,586,404 | 7.5% |
| Ascendis Pharma A/S | February 14, 2023 | 4,954,855 | 8.7% |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-06-05 |
| 4 | 2023-06-02 |
| 4 | 2023-06-02 |
| SC 13D/A | 2023-06-02 |
| 4 | 2023-05-24 |
| 4 | 2023-05-24 |
| SC 13D/A | 2023-05-24 |
| SC 13D/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-05 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.